Abstract Treatment of acute myocardial infarction (AMI) has improved significantly in recent
years, but many patients have adverse left ventricular (LV) remodeling, a maladaptive …

Objective This collaboration between the American College of Rheumatology and the
American Association of Hip and Knee Surgeons developed an evidence‐based guideline …

Objective To investigate the rate of serious bacterial, viral or opportunistic infection in
patients with rheumatoid arthritis (RA) starting tocilizumab (TCZ) versus tumour necrosis …

Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis (RA). Tofacitinib modulates the signaling of cytokines that are integral to lymphocyte …

Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …

Christopher R. Holroyd1, Rakhi Seth1, Marwan Bukhari2, Anshuman Malaviya3, Claire
Holmes1, Elizabeth Curtis4, Christopher Chan1, Mohammed A. Yusuf3, Anna Litwic4, 5 …

Background The inflammatory contribution to type 2 diabetes (T2D) has suggested new
therapeutic targets using biologic drugs designed for rheumatoid arthritis (RA). On this basis …

Autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease,
psoriasis, and others, are characterized by dysregulation of various aspects of normal …

Patients with rheumatoid arthritis (RA) have a greater risk of developing both Hodgkin
lymphoma (HL) and non‐HL than the general population. Non‐Hodgkin lymphoma is more …

Monoclonal antibodies (mAbs) are increasingly used to treat rheumatoid arthritis (RA). At
present, anti-tumor necrosis factor-α drugs (infliximab, adalimumab, certolizumab pegol, and …